Clinical and Applied Thrombosis/Hemostasis

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to start reading!

SAEGTRACK

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1076029607304239v1
14/3/267    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Google Scholar
Right arrow Articles by Ellery, P. E.R.
Right arrow Articles by Adams, M. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ellery, P. E.R.
Right arrow Articles by Adams, M. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
This version was published on July 1, 2008
Clinical and Applied Thrombosis/Hemostasis, Vol. 14, No. 3, 267-278 (2008)
DOI: 10.1177/1076029607304239

Further Insight Into the Heparin-Releasable and Glycosylphosphatidylinositol-Lipid— Anchored Forms of Tissue Factor Pathway Inhibitor

Paul E.R. Ellery, BSc (Hons)

Western Australia Biomedical Research Institute, Curtin University of Technology

Kathy Hardy, PhD

Western Australia Biomedical Research Institute, Curtin University of Technology, Cyto Labs, Bentley, Perth, Western Australia

Robert Oostryck, MSc

Western Australia Biomedical Research Institute, Curtin University of Technology

Murray J. Adams, PhD

Western Australia Biomedical Research Institute, Curtin University of Technology, Murray.Adams{at}utas.edu.au, School of Human Life Sciences, University of Tasmania, Launceston, Tasmania Australia

The release of tissue factor pathway inhibitor (TFPI) from human umbilical vein endothelial cells (HUVECs) was investigated using heparin and phospholipase C. The experiment included incubating HUVECs with 0, 1, or 10 U/mL heparin diluted in Dulbecco Modified Eagle's Medium plus 5% fetal calf serum for 1 or 24 hours. A statistically significant increase in TFPI activity levels was seen at 1 hour, but not at 24 hours. A 20-fold increase in the release of TFPI after phospholipase C treatment of HUVECs was demonstrated, confirming that it is glycosylphosphatidylinositol-lipid (GPI) anchored. Sequential treatment of HUVECs with phospholipase C and heparin was performed, and a trend was observed where GPI-anchored TFPI levels were increased after 1 hour of pretreatment with heparin but were decreased after 24 hours. Serum is a requirement for the heparin-dependent release of TFPI from HUVECs. Heparin pretreatment of HUVECs may affect levels of GPI anchored TFPI in a time and dose-dependent manner.

Key Words: glycosylphosphatidylinositol-lipid anchor • heparin • tissue factor pathway inhibitor


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?